Myeloma in the real world: What is really happening?

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. Until now, most outcome data for MM have come from clinical trials, with few reports available on patients treated outside the clinical trial setting-in the "real world." Clinical trials are routinely undertaken in specialist centers, and extrapolation of these trial data to broader clinical practice might not accurately reflect "real-world" patient outcomes. Optimal management of MM is of key importance for positive patient outcomes, and further scrutiny of the efficacy and safety of the various reported therapies and how clinical trial findings are being translated or applied in the real-world management of MM is required. In the present review, we have described the minimal published evidence available through a comprehensive published data search of MEDLINE using the OvidSP interface on the management and outcomes of MM outside the setting of clinical trials, including evidence on the uptake of new therapies and their efficacy and tolerability in standard practice. Clinical registries might be able to help provide these data in the future.

Original languageEnglish
Pages (from-to)133-144.e1
Number of pages13
JournalClinical Lymphoma, Myeloma & Leukemia
Volume17
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Keywords

  • Clinical practice
  • Efficacy
  • Practice patterns
  • Safety
  • Treatment paradigm

Cite this

@article{387f556bd6044e729c9d83a10c768bd0,
title = "Myeloma in the real world: What is really happening?",
abstract = "Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. Until now, most outcome data for MM have come from clinical trials, with few reports available on patients treated outside the clinical trial setting-in the {"}real world.{"} Clinical trials are routinely undertaken in specialist centers, and extrapolation of these trial data to broader clinical practice might not accurately reflect {"}real-world{"} patient outcomes. Optimal management of MM is of key importance for positive patient outcomes, and further scrutiny of the efficacy and safety of the various reported therapies and how clinical trial findings are being translated or applied in the real-world management of MM is required. In the present review, we have described the minimal published evidence available through a comprehensive published data search of MEDLINE using the OvidSP interface on the management and outcomes of MM outside the setting of clinical trials, including evidence on the uptake of new therapies and their efficacy and tolerability in standard practice. Clinical registries might be able to help provide these data in the future.",
keywords = "Clinical practice, Efficacy, Practice patterns, Safety, Treatment paradigm",
author = "Krystal Bergin and Zoe McQuilten and Elizabeth Moore and Erica Wood and Andrew Spencer",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.clml.2016.12.002",
language = "English",
volume = "17",
pages = "133--144.e1",
journal = "Clinical Lymphoma, Myeloma & Leukemia",
issn = "2152-2650",
publisher = "Elsevier",
number = "3",

}

Myeloma in the real world: What is really happening? / Bergin, Krystal; McQuilten, Zoe; Moore, Elizabeth; Wood, Erica; Spencer, Andrew.

In: Clinical Lymphoma, Myeloma & Leukemia, Vol. 17, No. 3, 01.03.2017, p. 133-144.e1.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Myeloma in the real world: What is really happening?

AU - Bergin, Krystal

AU - McQuilten, Zoe

AU - Moore, Elizabeth

AU - Wood, Erica

AU - Spencer, Andrew

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. Until now, most outcome data for MM have come from clinical trials, with few reports available on patients treated outside the clinical trial setting-in the "real world." Clinical trials are routinely undertaken in specialist centers, and extrapolation of these trial data to broader clinical practice might not accurately reflect "real-world" patient outcomes. Optimal management of MM is of key importance for positive patient outcomes, and further scrutiny of the efficacy and safety of the various reported therapies and how clinical trial findings are being translated or applied in the real-world management of MM is required. In the present review, we have described the minimal published evidence available through a comprehensive published data search of MEDLINE using the OvidSP interface on the management and outcomes of MM outside the setting of clinical trials, including evidence on the uptake of new therapies and their efficacy and tolerability in standard practice. Clinical registries might be able to help provide these data in the future.

AB - Multiple myeloma (MM) is the second most common hematologic malignancy and is predominantly a disease of the elderly. In the past 2 decades, a range of new therapeutic options have become available, leading to improvements in patient outcomes, including both attainment of remission and overall survival. These improved outcomes have heralded a paradigm shift from a palliative approach toward more active management, including the use of sequential therapies, with the goal of prolonging progression-free and overall survival and preserving organ function to enable delivery of further therapy at relapse. Until now, most outcome data for MM have come from clinical trials, with few reports available on patients treated outside the clinical trial setting-in the "real world." Clinical trials are routinely undertaken in specialist centers, and extrapolation of these trial data to broader clinical practice might not accurately reflect "real-world" patient outcomes. Optimal management of MM is of key importance for positive patient outcomes, and further scrutiny of the efficacy and safety of the various reported therapies and how clinical trial findings are being translated or applied in the real-world management of MM is required. In the present review, we have described the minimal published evidence available through a comprehensive published data search of MEDLINE using the OvidSP interface on the management and outcomes of MM outside the setting of clinical trials, including evidence on the uptake of new therapies and their efficacy and tolerability in standard practice. Clinical registries might be able to help provide these data in the future.

KW - Clinical practice

KW - Efficacy

KW - Practice patterns

KW - Safety

KW - Treatment paradigm

UR - http://www.scopus.com/inward/record.url?scp=85010931373&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2016.12.002

DO - 10.1016/j.clml.2016.12.002

M3 - Review Article

VL - 17

SP - 133-144.e1

JO - Clinical Lymphoma, Myeloma & Leukemia

JF - Clinical Lymphoma, Myeloma & Leukemia

SN - 2152-2650

IS - 3

ER -